Attempts to overcome the resistance of MSS CRC to ICIs are currently ongoing with the combined administration of various therapeutics targeting MEK, STING, VEGFR, or WNT, or using oncolytic viruses. The gene discussed is STING1; the disease is colorectal carcinoma.